DAFNA Capital Management’s Astria Therapeutics ATXS Stock Holding History

DAFNA Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-304,775	Closed	-$3.99M	–	84
2025 Q4	$3.99M	Sell	304,775 -15,000	-5%	-$179K	0.93%	26
2025 Q3	$2.33M	Sell	319,775 -5,000	-2%	-$33.8K	0.58%	41
2025 Q2	$1.74M	Buy	324,775 +10,000	+3%	+$48.5K	0.48%	39
2025 Q1	$1.68M	Buy	314,775 +15,000	+5%	+$105K	0.48%	42
2024 Q4	$2.68M	Buy	299,775 +45,610	+18%	+$484K	0.68%	31
2024 Q3	$2.8M	Sell	254,165 -20,000	-7%	-$222K	0.66%	39
2024 Q2	$2.49M	Buy	274,165 +50,900	+23%	+$497K	0.6%	38
2024 Q1	$3.14M	Sell	223,265 -225,743	-50%	-$2.81M	0.72%	34
2023 Q4	$3.45M	Buy	449,008 +153,515	+52%	+$849K	0.83%	36
2023 Q3	$2.2M	Buy	295,493 +167,840	+131%	+$1.43M	0.69%	37
2023 Q2	$1.06M	Buy	127,653 +57,770	+83%	+$667K	0.29%	52
2023 Q1	$929K	Buy	+69,883	New	+$945K	0.28%	47

DAFNA Capital Management's ATXS Position: Q1 2026 in Review

DAFNA Capital Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 304,775 shares — an estimated $3.99M sold.

DAFNA Capital Management first reported a position in ATXS in Q1 2023 and held it in 12 quarters. The position peaked at $3.99M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

DAFNA Capital Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
DAFNA Capital Management sold 304,775 Astria Therapeutics shares in Q1 2026, an estimated $3.99M.
DAFNA Capital Management first reported a position in Astria Therapeutics in Q1 2023 and held it in 12 quarters.
DAFNA Capital Management's Astria Therapeutics position peaked at $3.99M in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.